36.01
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt HROW?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$37.08
Offen:
$37.2
24-Stunden-Volumen:
248.37K
Relative Volume:
0.57
Marktkapitalisierung:
$1.32B
Einnahmen:
$154.15M
Nettoeinkommen (Verlust:
$-33.58M
KGV:
-37.51
EPS:
-0.96
Netto-Cashflow:
$-20.74M
1W Leistung:
+4.42%
1M Leistung:
+17.06%
6M Leistung:
+3.88%
1J Leistung:
+41.97%
Harrow Inc Stock (HROW) Company Profile
Firmenname
Harrow Inc
Sektor
Telefon
615.733.4731
Adresse
1A BURTON HILLS BLVD, NASHVILLE, CA
Vergleichen Sie HROW mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
HROW
Harrow Inc
|
35.95 | 1.31B | 154.15M | -33.58M | -20.74M | -0.96 |
![]()
ZTS
Zoetis Inc
|
149.38 | 69.30B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.54 | 47.50B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
HLN
Haleon Plc Adr
|
9.605 | 44.47B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.18 | 18.83B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
297.48 | 13.43B | 2.99B | 1.21B | 1.13B | 25.06 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-07-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
2025-06-12 | Eingeleitet | BTIG Research | Buy |
2025-06-10 | Eingeleitet | William Blair | Outperform |
2025-02-06 | Eingeleitet | H.C. Wainwright | Buy |
2024-12-04 | Bestätigt | B. Riley Securities | Buy |
2024-04-11 | Eingeleitet | Craig Hallum | Buy |
2022-09-08 | Fortgesetzt | B. Riley Securities | Buy |
2021-10-14 | Fortgesetzt | B. Riley Securities | Buy |
2021-09-24 | Eingeleitet | Aegis Capital | Buy |
2021-07-02 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Harrow Inc Aktie (HROW) Neueste Nachrichten
Is Harrow Inc. a good long term investmentRapid capital growth - jammulinksnews.com
What analysts say about Harrow Inc. stockDynamic capital growth - jammulinksnews.com
What drives Harrow Inc. stock priceMarket-beating returns - Autocar Professional
Harrow, Inc. (HROW): A Bull Case Theory - Insider Monkey
Harrow Inc. Stock Analysis and ForecastMassive wealth growth - PrintWeekIndia
Harrow jumps as Cantor initiates with Bullish view on conservative outlook - MSN
HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm - ETX View
Ladenburg Thalmann & Co. Keeps Their Buy Rating on Harrow Health (HROW) - The Globe and Mail
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW - FinancialContent
Harrow purchases US commercialization rights to Samsung Bioepis' biosimilar portfolio - Eyes On Eyecare
Samsung Bioepis Partners with Harrow to Expand US Ophthalmology Market - Asia Business Outlook
Harrow's Strategic Positioning in the $9B Ophthalmology Biosimilars Market: Unlocking Value Through Biosimilar Commercialization and Medicare Savings - AInvest
Samsung Bioepis signs U.S. partnership for ophthalmology biosimilar sales - Yonhap News Agency
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc.HROW - cnhinews.com
Harrow Enters Into Commercialization Agreement With Samsung Bioepis For Ophthalmology Biosimilars Portfolio In The United States - TradingView
Harrow Enters into Commercialization Agreement with Samsung Bioe - GuruFocus
Harrow acquires exclusive US rights to Samsung Bioepis eye drugs - Investing.com Australia
Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States - Business Wire
Harrow Secures Landmark Deal for First FDA-Approved Eye Disease Biosimilars from Samsung Bioepis - Stock Titan
Q2 Earnings Estimate for Harrow Issued By William Blair - Defense World
(HROW) Trading Report - news.stocktradersdaily.com
FY2026 Earnings Estimate for Harrow Issued By William Blair - Defense World
Why Harrow Inc. stock attracts strong analyst attentionBreakout Level Watch - Newser
How Harrow Inc. stock performs during market volatilityTop Performing Stocks - Newser
What makes Harrow Inc. stock price move sharplyFree Stock Portfolio Optimization - Newser
Harrow (HROW) Stock Jumps 11.4%: Will It Continue to Soar? - Yahoo Finance
HROW’s Stock Performance: A Year of Mixed Fortunes & Market Shifts - investchronicle.com
Harrow (NASDAQ:HROW) Coverage Initiated at Cantor Fitzgerald - Defense World
Harrow Shares Soar 11.35% on Cantor Fitzgerald's Overweight Rating - AInvest
Harrow's Internal $100 Price Target Is Ambitious, But New Bloomberg Data Backs It Up - Seeking Alpha
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Harrow stock jumps on Cantor Bullish view (HROW:NASDAQ) - Seeking Alpha
Cantor Fitzgerald Initiates Harrow at Overweight With $76 Price Target - MarketScreener
Betting on Ophthalmic Growth Amid Strong Analyst Backing: Harrow, Inc.'s Strategic Play - AInvest
Harrow: Immense Upside Potential (NASDAQ:HROW) - Seeking Alpha
Finanzdaten der Harrow Inc-Aktie (HROW)
Umsatz
Nettogewinn
Free Cashflow
ENV
Harrow Inc-Aktie (HROW) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Opaleye Management Inc. | 10% Owner |
Jun 09 '25 |
Sale |
30.37 |
15,204 |
461,794 |
105,000 |
Opaleye Management Inc. | 10% Owner |
Jun 03 '25 |
Sale |
30.04 |
3,000 |
90,116 |
122,000 |
Opaleye Management Inc. | 10% Owner |
Jun 04 '25 |
Sale |
30.02 |
1,796 |
53,907 |
120,204 |
Opaleye Management Inc. | 10% Owner |
May 12 '25 |
Sale |
25.90 |
10,000 |
258,959 |
130,000 |
Opaleye Management Inc. | 10% Owner |
May 13 '25 |
Sale |
26.59 |
5,000 |
132,945 |
125,000 |
BOLL ANDREW R. | Chief Financial Officer |
Apr 03 '25 |
Option Exercise |
0.00 |
346,500 |
0 |
914,589 |
SAHAREK JOHN P. | CEO & President, ImprimisRx |
Apr 03 '25 |
Option Exercise |
0.00 |
277,200 |
0 |
576,863 |
BAUM MARK L | Chief Executive Officer |
Apr 03 '25 |
Option Exercise |
0.00 |
762,300 |
0 |
2,899,825 |
Opaleye Management Inc. | 10% Owner |
Mar 18 '25 |
Sale |
30.01 |
5,000 |
150,055 |
140,000 |
Opaleye Management Inc. | 10% Owner |
Mar 18 '25 |
Sale |
29.64 |
5,000 |
148,200 |
145,000 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):